Many pediatricians have had this moment in clinic: a patient returns for a follow-up weight check after months of conversations about nutrition, physical activity, and screen time — and the number on the scale hasn’t budged. Maybe it has even gone up.
For years, the typical response was to double down on lifestyle counseling and try again. But the conversation around pediatric obesity is changing. In 2023, the American Academy of Pediatrics released updated guidelines encouraging clinicians to treat pediatric obesity as a chronic disease, using the full range of tools available.
These guidelines emphasize that pediatric obesity treatment now includes lifestyle interventions, anti-obesity medications, and bariatric surgery.
For many clinicians, that shift raises an important question: How do we actually incorporate these treatments into everyday pediatric practice?
One of the most important changes in the new guidelines isn’t a medication or a procedure. It’s the mindset.
Pediatric obesity isn’t simply the result of poor choices or lack of motivation. It’s a complex chronic disease shaped by genetics, biology, environment, and social factors.
That means the old “watch and wait” model doesn’t serve our patients well. Instead, we approach obesity the same way we approach asthma or diabetes: identify it early and treat it proactively.
Of course, lifestyle changes still matter. But they often don’t work. And many pediatricians practice in settings where access to dietitians, obesity clinics, or structured lifestyle programs is limited.
The key message from experts in the field is simple: do the best you can with what you have.
Even small steps — nutrition counseling, connecting families with school resources, or encouraging realistic activity goals — can help change a child’s long-term health trajectory.
And when lifestyle strategies alone aren’t enough, medications can play an important role.
The toolbox for pediatric obesity treatment has expanded significantly in recent years.
Common oral medications include:
Among these, the phentermine–topiramate combination tends to produce the greatest weight loss and is FDA-approved for adolescents aged 12 and older. Because insurance coverage for the combination pill can be inconsistent, some clinicians prescribe the medications separately — phentermine in the morning and topiramate at night.
One advantage of oral medications is accessibility. They are generally inexpensive and widely available at pharmacies, making them practical first-line options for many primary care practices.
Oral medications are often the most accessible starting point for clinicians. But in recent years, another class of medications has dramatically changed the obesity treatment landscape.
Much of the recent excitement in obesity medicine centers on injectable GLP-1 receptor agonists, particularly semaglutide.
These medications influence brain–gut signaling pathways that regulate hunger and satiety. Clinically, they reduce appetite, slow gastric emptying, and help patients feel full sooner.
The challenge is access. Insurance coverage varies widely, and out-of-pocket costs can be substantial.
Beyond weight loss, these medications may also improve obesity-related complications. For example, semaglutide recently received FDA approval to treat metabolic dysfunction–associated steatotic liver disease (MASLD) in adults, with pediatric studies underway.
Many pediatricians reach for metformin when they see insulin resistance or acanthosis nigricans. While it can improve insulin sensitivity and may make acanthosis look better, metformin is not an effective weight-loss medication.
The underlying driver of beta-cell dysfunction is excess adiposity itself, meaning that meaningful weight reduction is usually the more important intervention. Metformin can still be reasonable when other medications aren’t accessible, but clinicians should recognize its limitations.
Another practical strategy is choosing medications that address more than one condition at the same time.
Many adolescents with obesity are also living with conditions like ADHD, depression, migraines, or anxiety. Some medications can target multiple issues simultaneously.
For example:
Using medications with these “dual benefits” can simplify treatment plans and improve overall outcomes.
As obesity medications become more effective, clinicians are seeing something that used to be rare in pediatric practice: meaningful weight loss.
With highly effective therapies, adolescents may lose 30–50 pounds over the course of a year.
That raises an important question: how do we support nutrition during weight loss, especially in clinics without dietitians?
One practical framework is the “60-60-60 rule”:
Prioritizing protein helps preserve lean muscle mass during weight loss, while hydration can reduce medication side effects like nausea or fatigue.
This approach helps keep daily calories in check and takes the focus away from calorie counting — something most families find difficult to sustain long term.
Many clinicians worry that medications will cause dangerously rapid weight loss. In reality, weight loss tends to follow a predictable pattern.
Patients often experience a rapid early drop during the first one to two months, followed by stabilization at a new metabolic set point. Some experts describe this as the “Nike swoosh” curve.
Most adolescents do not drop to a normal BMI percentile. Instead, they typically move down one obesity category, for example, from class III obesity to class II.
Even that shift can significantly improve metabolic health and reduce long-term complications.
Management becomes more complicated for children under age 12.
These patients often carry the highest lifetime risk of obesity-related complications, particularly when excess weight begins early in childhood.
Medication options are more limited and often used off-label. In practice, clinicians may consider:
Liraglutide is another GLP-1 medication currently approved for adolescents and under review for use in children as young as six years old. While somewhat less effective than semaglutide, it may become an important option as additional approvals emerge.
One surprising takeaway from recent research is how underutilized bariatric surgery remains.
The most common procedure is laparoscopic sleeve gastrectomy, which removes about 70% of the stomach and lowers production of the hunger hormone ghrelin. This helps reset appetite regulation and energy balance.
The AAP guidelines recommend considering bariatric surgery for adolescents with severe obesity (class II or III) when other treatments are insufficient.
Adolescents often lose around 100 pounds in the first year, and many obesity-related conditions go into remission. Complication rates are low, comparable to common surgeries like appendectomy.
Pediatric obesity care is evolving quickly, and the tools available to clinicians are expanding. Lifestyle counseling remains an essential foundation, but for many patients, it isn’t enough on its own.
Medications and bariatric surgery won’t be the right choice for every child. But when used thoughtfully, they can change the trajectory of a patient’s health — preventing diabetes, improving metabolic disease, and helping families move beyond years of frustrating weight conversations.
For clinicians, the goal isn’t perfection. It’s progress, and having more tools in the toolbox helps us get there.
To learn more, listen to Peds Reviews and Perspectives podcast chapter, "Prescribing Medications for Pediatric Obesity: Pt 1" and "Prescribing Medications for Pediatric Obesity: Pt 2."
What is the most effective medication for pediatric obesity?
GLP-1 agonists such as semaglutide produce the greatest weight loss in adolescents, though cost and access can limit use.
When should medications be started for pediatric obesity?
The AAP recommends considering anti-obesity medications for children aged 12 and older with obesity when lifestyle interventions alone are not sufficient.
Are GLP-1 medications safe for adolescents with obesity?
GLP-1 agonists such as semaglutide and liraglutide are FDA-approved for adolescents aged 12 and older and have been shown to be safe and effective when used under medical supervision. The most common side effects are gastrointestinal, such as nausea and vomiting.